Vixen Pharmaceuticals' Acquisition

Vixen Pharmaceuticals was acquired by Aclaris Therapeutics on March 29, 2016.

Vixen Pharmaceuticals holds intellectual property rights, obtained from Columbia University, that cover the uses of certain Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata,…

Articles about Vixen Pharmaceuticals' Acquisition: